<![CDATA[Objective: The objective was to examine cervical cytology findings
from conventional Pap smear examination in Depo-Provera®
and Cyclofem® acceptor in one-year period.
Method: The study design is descriptive observational involving
35 Depo-Provera® and 35 Cyclofem® acceptor. We follow up their
cytology findings prospectively. This study was conduct in FER
and gynecology clinics at Dr. Kariadi Hospital Semarang also at
Halmahera and Ngesrep public health service.
The subjects were women, aged 20 - 40 years old who chosen
Depo-Provera® and Cyclofem® as their contraceptive methods. This
study began on December 2006, all subjects who met inclusion criteria
underwent initial cytology screening. On December 2007, and
there were 70 subjects. They underwent cytology examination at
month sixth (simultaneously with third Depo-Provera® injection and
seventh Cyclofem® injection) and at month twelve (simultaneously
with fifth Depo-Provera® injection and thirteenth Cyclofem® injection).
Distribution frequency was analyzed using univariate analysis
and data shown as mean and standard deviation whereas bivariate
analysis was conduct with X2 and t-test. Cytology examination was
conduct in anatomy pathology laboratory at Medicine Faculty,
Diponegoro University/Dr. Kariadi Hospital, Semarang.
Result: Inflammation rates tend to increase on Depo-Provera®
group compare to Cyclofem® group. At first cytology result there is
no difference between two groups, it suggest that both groups had
same baseline characteristic. Thereafter, at second and third examination,
Depo-Provera® group significantly showed higher inflammation
and dysplasia rates compare to Cyclofem® group.
Conclusion: After one-year period, there was difference on cervical
cytology results that is inflammation rates which higher on
Depo- Provera® acceptor compare to Cyclofem®.
[Indones J Obstet Gynecol 2009; 33-4: 233-8]
Keywords: pap smear, Depo-Provera®, Cyclofem®, Pap smear
on hormonal contraception]]>
